Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Merck builds in CNS diseases with $576m Calporta buyMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category Share XMerck builds in CNS diseases with $576m Calporta buyhttps://pharmaphorum.com/news/merck-builds-in-cns-diseases-with-576m-calporta-buy/
Allergan pays $750m to avoid Alzheimer’s drug lawsuitAllergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of Share XAllergan pays $750m to avoid Alzheimer’s drug lawsuithttps://pharmaphorum.com/news/allergan-pays-750m-to-avoid-alzheimers-drug-lawsuit/
Surprise! Biogen says Alzheimer’s drug works after all and will be filedMere months ago Biogen’s Alzheimer’s drug aducanumab was being written off as the latest amyloid-targeting dud. Now, its Share XSurprise! Biogen says Alzheimer’s drug works after all and will be filedhttps://pharmaphorum.com/news/surprise-biogen-says-alzheimers-drug-works-after-all-and-will-be-filed/
Last BACE bombs: Eisai, Biogen give up on elenbecestatThe final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been Share XLast BACE bombs: Eisai, Biogen give up on elenbecestathttps://pharmaphorum.com/news/last-bace-bombs-eisai-biogen-give-up-on-elenbecestat/
Listening to the patient voice: Why developing new dementia treatments is everyone’s jobDeveloping life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and Share XListening to the patient voice: Why developing new dementia treatments is everyone’s jobhttps://pharmaphorum.com/views-and-analysis/listening-to-the-patient-voice-why-developing-new-dementia-treatments-is-everyones-job/
Pilot study suggests smart devices could help spot early dementiaA preliminary study run by Eli Lilly, Apple and Evidation has suggested that connected smart devices can detect Share XPilot study suggests smart devices could help spot early dementiahttps://pharmaphorum.com/news/pilot-study-suggests-smart-devices-could-help-spot-early-dementia/
AC Immune trials Alzheimer’s vaccineSwitzerland’s AC Immune biopharma has begun mid-stage trials of a vaccine against Alzheimer’s disease and Abeta-related cognitive decline Share XAC Immune trials Alzheimer’s vaccinehttps://pharmaphorum.com/news/ac-immune-trials-alzheimers-vaccine/
Philanthropists donate $30m towards finding Alzheimer’s cureA coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Share XPhilanthropists donate $30m towards finding Alzheimer’s curehttps://pharmaphorum.com/news/philanthropists-donate-30m-towards-finding-alzheimers-cure/
